-
Ocugen NASDAQ:OCGN Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.
Location: 5 Great Valley Pkwy Ste 160, Pennsylvania, 19355, US | Website: ocugen.com | Industry: Sanitary Paper Product Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
192.6M
Cash
38.7M
Avg Qtr Burn
N/A
Short % of Float
18.41%
Insider Ownership
1.27%
Institutional Own.
27.53%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OCU400 Details Retinitis Pigmentosa | BLA Submission | |
NeoCart® (Autologous chondrocyte-derived neocartilage) Details Articular cartilage defects in the knee | Phase 3 Initiation | |
OCU410 Details Geographic atrophy, Age-related macular degeneration | Phase 1/2 Data readout | |
OCU400 Details Eye disease , Leber congenital amaurosis | Phase 1/2 Data readout | |
OCU410ST Details Stargardt disease, Rare genetic disease | Phase 1/2 Update | |
OCU200 Details Diabetic macular edema | Phase 1 Data readout | |
COVAXIN (BBV152) Details COVID-19, Infectious disease | Failed Discontinued |